Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma.
暂无分享,去创建一个
Yang Guo | Andrew C Larson | Grace M Nijm | Rachel Klein | Reed A Omary | Guang-Yu Yang | A. Sahakian | R. Omary | A. Larson | G. Nijm | Alan V Sahakian | Guang-Yu Yang | R. Klein | Yue Zhang | Yue Zhang | Yang Guo
[1] J. Hinshaw,et al. Cryoablation for liver cancer. , 2007, Techniques in vascular and interventional radiology.
[2] P. Foubert,et al. Integrin α4β1 signaling is required for lymphangiogenesis and tumor metastasis (Cancer Research (2010) 70, (3042-51) DOI , 2010 .
[3] W. Lau,et al. The Current Role of Radiofrequency Ablation in the Management of Hepatocellular Carcinoma: A Systematic Review , 2009, Annals of surgery.
[4] M. Najimi,et al. Hepatocyte apoptosis. , 2009, Methods in molecular biology.
[5] J. Bruix,et al. Management of hepatocellular carcinoma , 2005, Hepatology.
[6] J. F. Burrows,et al. Tumor and Stem Cell Biology Cancer Research The Deubiquitinating Enzyme USP 17 Is Highly Expressed in Tumor Biopsies , Is Cell Cycle Regulated , and Is Required for G 1S Progression , 2010 .
[7] C. Croce,et al. Oncogenic role of miR-483-3p at the IGF2/483 locus. , 2010, Cancer research.
[8] J. Charboneau,et al. Technologies for ablation of hepatocellular carcinoma. , 2008, Gastroenterology.
[9] J. Bruix,et al. Novel advancements in the management of hepatocellular carcinoma in 2008. , 2008, Journal of hepatology.
[10] Carlo Bartolozzi,et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. , 2005, Radiology.
[11] H. Gaylord,et al. AMERICAN ASSOCIATION FOR CANCER RESEARCH. , 1913, California state journal of medicine.
[12] H. Fukuda,et al. European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .
[13] P. Liang,et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. , 2005, Radiology.
[14] A. Novikoff,et al. A transplantable rat liver tumor induced by 4-dimethylaminoazobenzene. , 1957, Cancer research.
[15] Yun Liang,et al. Technical aspects of imaging and transfemoral arterial treatment of N1-S1 tumors in rats: an appropriate model to test the biology and therapeutic response to transarterial treatments of liver cancers. , 2009, Journal of vascular and interventional radiology : JVIR.
[16] Wang Qi,et al. Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma in Elderly Patients , 2009 .
[17] P. Fisher,et al. Molecular mechanism of chemoresistance by astrocyte elevated gene-1. , 2010, Cancer research.
[18] T. Kawabe,et al. Radiofrequency ablation for hepatocellular carcinoma in so‐called high‐risk locations , 2006, Hepatology.
[19] Wei Lu,et al. Tumor Site–Specific Silencing ofNF-κB p65by Targeted Hollow Gold Nanosphere–Mediated Photothermal Transfection , 2010, Cancer Research.
[20] D Miklavcic,et al. A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy. , 2000, Biochimica et biophysica acta.
[21] Boris Rubinsky,et al. Cancer Cells Ablation with Irreversible Electroporation , 2005, Technology in cancer research & treatment.
[22] Boris Rubinsky,et al. Tumor Ablation with Irreversible Electroporation , 2007, PloS one.
[23] M Deimling,et al. Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: technique and prospective results. , 1995, Radiology.
[24] M. Varma,et al. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature , 2005, Histopathology.
[25] J. Benoit,et al. Description and technical pitfalls of a hepatoma model and of intra-arterial injection of radiolabelled lipiodol in the rat , 2005, Laboratory animals.
[26] A. Burroughs,et al. Hepatocellular carcinoma , 2003, The Lancet.
[27] G. Mills,et al. Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. , 2010, Cancer research.
[28] H. Rhim. Complications of radiofrequency ablation in hepatocellular carcinoma , 2005, Abdominal Imaging.
[29] S. M. Lobo,et al. Improved coagulation with saline solution pretreatment during radiofrequency tumor ablation in a canine model. , 2002, Journal of vascular and interventional radiology : JVIR.
[30] Boris Rubinsky,et al. Optimal parameters for the destruction of prostate cancer using irreversible electroporation. , 2008, The Journal of urology.
[31] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[32] J. Bruix,et al. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma , 1992, Hepatology.
[33] Boris Rubinsky,et al. Irreversible Electroporation: Implications for Prostate Ablation , 2007, Technology in cancer research & treatment.
[34] W. Lu,et al. Tumor site-specific silencing of NF-κB p65 by targeted hollow gold nanosphere-mediated photothermal transfection (Cancer Research (2010) 70, (3177-3188) DOI: 10.1158/0008-5472.CAN-09-3379) , 2010 .
[35] J. Vincent,et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.
[36] Jon F Edd,et al. Mathematical Modeling of Irreversible Electroporation for Treatment Planning , 2007, Technology in cancer research & treatment.
[37] J. Chien,et al. Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. , 2010, Cancer research.
[38] L. Mir,et al. A Study of the Immunological Response to Tumor Ablation with Irreversible Electroporation , 2007, Technology in cancer research & treatment.
[39] Boris Rubinsky,et al. Irreversible Electroporation: A New Ablation Modality — Clinical Implications , 2007, Technology in cancer research & treatment.
[40] T. Livraghi,et al. Percutaneous Ethanol Injection in the treatment of hepatocellular carcinoma in cirrhosis. , 1998, Hepato-gastroenterology.
[41] Boris Rubinsky,et al. The Effect of Irreversible Electroporation on Blood Vessels , 2007, Technology in cancer research & treatment.
[42] R. Hoffman,et al. The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. , 2010, Cancer research.
[43] A. Harris,et al. Histological quantitation of tumour angiogenesis , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[44] P. Hsu,et al. Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma – a long‐term follow‐up study , 2008, Alimentary pharmacology & therapeutics.
[45] T. Schall,et al. Tumor and Stem Cell Biology Cancer Research The Chemokine Receptor CXCR 7 Is Highly Expressed in Human Glioma Cells and Mediates Antiapoptotic Effects , 2010 .
[46] Shinpei Sato,et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma , 2005, Cancer.
[47] Adrian Fisher,et al. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. , 2003, Journal of the American College of Surgeons.
[48] E F Halpern,et al. Radio-frequency tissue ablation: effect of pharmacologic modulation of blood flow on coagulation diameter. , 1998, Radiology.
[49] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[50] G. Gores,et al. Caspase inhibition reduces apoptotic death of cryopreserved porcine hepatocytes , 2001, Hepatology.
[51] H. Rhim,et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies , 2009, Hepatology.
[52] J. F. Burrows,et al. The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression. , 2010, Cancer research.
[53] A. Muotri,et al. Coordination of centrosome homeostasis and DNA repair is intact in MCF-7 and disrupted in MDA-MB 231 breast cancer cells. , 2010, Cancer research.
[54] Jing Ma,et al. Immunohistochemical expression of BRCA1 and lethal prostate cancer. , 2010, Cancer research.
[55] B. Rubinsky,et al. Tissue Ablation with Irreversible Electroporation , 2005, Annals of Biomedical Engineering.
[56] M. Kloor,et al. Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers. , 2010, Cancer research.
[57] Boris Rubinsky,et al. Temperature considerations during irreversible electroporation , 2008 .
[58] Chris T. Harvey,et al. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. , 2010, Cancer research.
[59] J. Chien,et al. Downregulation of HtrA 1 Promotes Resistance to Anoikis and Peritoneal Dissemination of Ovarian Cancer Cells , 2010 .
[60] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[61] W R Lees,et al. Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. , 2000, Radiographics : a review publication of the Radiological Society of North America, Inc.
[62] Boris Rubinsky,et al. In vivo results of a new focal tissue ablation technique: irreversible electroporation , 2006, IEEE Transactions on Biomedical Engineering.
[63] R. D. Hunter,et al. WHO Handbook for Reporting Results of Cancer Treatment , 1980 .
[64] Stephen T Kee,et al. Imaging Guided Percutaneous Irreversible Electroporation: Ultrasound and Immunohistological Correlation , 2007, Technology in cancer research & treatment.
[65] T. Livraghi,et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. , 1995, Radiology.
[66] J. Heath,et al. Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification. , 2010, Cancer research.
[67] H. Kung,et al. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. , 2010, Cancer research.